Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators.
about
Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosisRole of interleukin 15 and interleukin 18 in inflammatory responseEarly response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1betaNF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destructionTranscriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors.Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cellsThe utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritisModulation of host cell signaling pathways as a therapeutic approach in periodontal diseaseSKLB023 blocks joint inflammation and cartilage destruction in arthritis models via suppression of nuclear factor-kappa B activation in macrophageThe rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?Brain-derived neurotrophic factor is regulated via MyD88/NF-κB signaling in experimental Streptococcus pneumoniae meningitis.Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis.Gene expression analysis as an aid to the identification of drug targets.Characterization of NF-kappa B/I kappa B proteins in zebra fish and their involvement in notochord development.Adenovirus-mediated gene transfer of mutated IkappaB kinase and IkappaBalpha reveal NF-kappaB-dependent as well as NF-kappaB-independent pathways of HAS1 activation.Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark?Cytokine regulation in RA synovial tissue: role of T cell/macrophage contact-dependent interactions.High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets.Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?Bone morphogenetic protein-7 promotes chondrogenesis in human amniotic epithelial cells.Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis.Lipid peroxidation-mediated inflammation promotes cell apoptosis through activation of NF-κB pathway in rheumatoid arthritis synovial cells.Targeting cytokines in autoimmunity: new approaches, new promise.Role of interleukin 18 in rheumatoid arthritis.Nuclear factor (NF)-kappaB proteins: therapeutic targets.The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritisThe role of leukocyte-stromal interactions in chronic inflammatory joint disease.From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation?Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha productionCells of the synovium in rheumatoid arthritis. Dendritic cells.NF-kappa B as a therapeutic target in autoimmune disease.From osteoarthritic synovium to synovial-derived cells characterization: synovial macrophages are key effector cells.The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis.Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis.Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.HMGB1-LPS complex promotes transformation of osteoarthritis synovial fibroblasts to a rheumatoid arthritis synovial fibroblast-like phenotypePathogenesis of joint destruction in rheumatoid arthritis.Are we moving in the right direction with osteoarthritis drug discovery?
P2860
Q24568066-D9993D63-4363-4714-A6DA-9A0FD5551CEDQ24675082-26481DDD-417D-4D1B-B601-E6719F79A449Q24800017-A72E8592-860F-40EC-B12D-B329940F09C7Q24805487-82507AC4-98D5-4F55-9DD8-C0884F75A455Q24806147-7F55C735-CC96-4222-AB29-C577C7E020BDQ24812982-44F604E7-1686-4EC2-845A-2B8312EF244FQ24816543-AEDF8B4A-9DDE-4557-A260-574F36F49218Q26852727-D15205FB-B751-448E-AF75-B3F24F8C2FC5Q28486238-C92AA605-F34D-4B22-9EDA-A7C733097681Q33782321-FCBBD0D8-0048-478C-A33F-B9B51597966EQ33799471-936B8B8F-6406-427B-8CD8-5C758CFF7B68Q33966333-F8616781-07F1-49BC-A0B1-1D1589746545Q34071292-8563D3D8-FCFA-4C2D-8442-01DD2D2AF652Q34074678-F4CFCD48-29E4-4D8D-B910-9D7E619161ACQ34189456-D48FB272-9704-4274-967F-6A267454E4D6Q34346048-00DE57F7-E675-4748-90A3-09C565B94CEEQ34463886-1B03DB8D-F136-41AF-8C35-72CCAA56DDF3Q34510718-0022C81A-1B9E-4B5F-B9C8-19BDBE088FAFQ34731191-27A51093-DD4C-4125-8F5F-0EEFF0AF328DQ34731216-602E3F1B-7A61-49A7-9D81-2308930FC310Q34962973-C54482DA-A4D5-412E-89B7-7DC9D2E4D3CBQ35013184-7C6BB580-09B0-4CD1-B6F3-4B1D1AD8B0B4Q35074047-358EA2AA-A8DD-4DF5-8252-C94F490C6707Q35110153-B65C1188-1D12-4F26-BC37-AC852B90B7AAQ35144028-520080E5-5ED1-4D00-AB82-5F3F98882ABCQ35553488-980F3C3A-3BDB-46AD-887E-672BCE795049Q35579356-3169D2EC-EFE8-4CE7-A44A-4EFFFA66A546Q35630135-E948EC33-3478-4669-B676-98F6D6CE217BQ36024449-0B114FED-E0A2-49D1-BCF4-4B57B18A0BD6Q36269632-F3391A89-45A8-434D-AAD5-BF01126F387CQ36370908-8724B1AF-FB15-4231-8426-EC62FA9090D2Q36392394-E6E37490-ABEE-4838-84CB-80CDD81975EEQ36709522-8E4B6D1F-9776-42F5-AFCD-64DD9D94D789Q36765451-59E50E22-A6FE-473A-9D57-F8E5C4446DD7Q36955377-58DD0C82-3A60-4838-9A4F-EF155A42750BQ37202065-F465DA65-6EE1-4571-AEC5-2963DBA238F4Q37515656-4D11331A-13C9-4138-B1A6-594D9D3007DDQ37620697-B66A78D8-62E9-4EEF-8309-25CF0B8338C5Q37843795-DD738304-38BC-47F8-B298-FCE1C2BD5245Q37956680-62752375-D267-451F-B059-76D9641D447C
P2860
Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Defining therapeutic targets b ...... s anti-inflammatory mediators.
@ast
Defining therapeutic targets b ...... s anti-inflammatory mediators.
@en
type
label
Defining therapeutic targets b ...... s anti-inflammatory mediators.
@ast
Defining therapeutic targets b ...... s anti-inflammatory mediators.
@en
prefLabel
Defining therapeutic targets b ...... s anti-inflammatory mediators.
@ast
Defining therapeutic targets b ...... s anti-inflammatory mediators.
@en
P2093
P2860
P356
P1476
Defining therapeutic targets b ...... s anti-inflammatory mediators.
@en
P2093
P2860
P304
P356
10.1073/PNAS.96.10.5668
P407
P577
1999-05-01T00:00:00Z